Cargando…

Single‐cell RNA‐seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma

BACKGROUND: Multiple myeloma (MM) is a clinically and biologically heterogeneous plasma‐cell malignancy. Despite extensive research, disease heterogeneity and relapse remain a big challenge in MM therapeutics. We tried to dissect this disease and identify novel biomarkers for patient stratification...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Haiyan, Li, Zifeng, Lu, Jing, Qiang, Wanting, Jiang, Sihan, Xu, Yaochen, Fu, Weijun, Zhai, Xiaowen, Zhou, Lin, Qian, Maoxiang, Du, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926895/ https://www.ncbi.nlm.nih.gov/pubmed/35297204 http://dx.doi.org/10.1002/ctm2.757

Ejemplares similares

Development and validation of prognostic implications of chromosome abnormalities algorithm for newly diagnosed multiple myeloma
por: Luo, Tiancheng, et al.
Publicado: (2020)

Incidence, clinical characteristics, and prognostic nomograms for patients with myeloid sarcoma: A SEER-based study
por: Xing, Ziping, et al.
Publicado: (2022)

Single-Cell RNA-seq Reveals Characteristics of Malignant Cells and Immune Microenvironment in Subcutaneous Panniculitis-Like T-Cell Lymphoma
por: Li, Zifeng, et al.
Publicado: (2021)

PB2138: ORAL REGIMEN SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): SAFETY ASSESSMENT AND OPTIMIZATION
por: Du, Juan, et al.
Publicado: (2023)

Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming
por: Liang, Yuanzheng, et al.
Publicado: (2022)

Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era
por: Zhou, Huixing, et al.
Publicado: (2023)

P926: ELEVATED SERUM LEVELS OF SOLUBLE B-CELL MATURATION ANTIGEN AS A PROGNOSTIC BIOMARKER FOR MULTIPLE MYELOMA
por: Du, Juan, et al.
Publicado: (2023)

P43 CIRCULATING CLONAL PLASMA CELLS AT START OF SALVAGE REGIMEN PROVIDE POWERFUL PROGNOSTICATION BIOMARKER IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE
por: Romano, A., et al.
Publicado: (2023)

Revealing the intratumoral heterogeneity of non-DS acute megakaryoblastic leukemia in single-cell resolution
por: Su, Narun, et al.
Publicado: (2022)

Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma
por: Chakraborty, Rajshekhar, et al.
Publicado: (2020)

The Landscape of Cytogenetic Aberrations in Light-Chain Amyloidosis with or without Coexistent Multiple Myeloma
por: He, Haiyan, et al.
Publicado: (2023)

Dysregulated circular RNAs are closely linked to multiple myeloma prognosis, with circ_0026652 predicting bortezomib-based treatment response and survival via the microRNA-608-mediated Wnt/β-catenin pathway
por: Li, Lu, et al.
Publicado: (2022)

Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients
por: Jones, John R., et al.
Publicado: (2019)

Natural History and Prognostic Factors at First Relapse in Multiple Myeloma
por: Wang, Chen, et al.
Publicado: (2020)

Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma
por: Bianchi, Giada, et al.
Publicado: (2014)

Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma
por: Reutter, Katrin, et al.
Publicado: (2020)

Evaluation of prognostic factors in patients with relapsed AML: Clonal evolution versus residual disease
por: Kim, Hyojeong, et al.
Publicado: (2016)

Single-Cell Transcriptomes Combining with Consecutive Genomics Reveal Clonal Evolution and Gene Regulatory Networks in Relapsed and Refractory Multiple Myeloma
por: Xu, Jiadai, et al.
Publicado: (2022)

Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils Novel Prognostic Biomarkers in Multiple Myeloma
por: Zhao, Jing, et al.
Publicado: (2022)

Down-Regulated FOXO1 in Refractory/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia
por: Zheng, Qingqing, et al.
Publicado: (2020)

Clonal diversity by asymmetry
por: Wells, William A.
Publicado: (2007)

Publisher Correction: Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma
por: Reutter, Katrin, et al.
Publicado: (2021)

Corrigendum: Down-Regulated FOXO1 in Refractory/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia
por: Zheng, Qingqing, et al.
Publicado: (2020)

Clonal Evolution of Multiple Myeloma—Clinical and Diagnostic Implications
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2021)

Molecular and immunological mechanisms of clonal evolution in multiple myeloma
por: Forster, Stefan, et al.
Publicado: (2023)

Pericardial relapse of multiple myeloma
por: Jamison, Lee S, et al.
Publicado: (2020)

Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?
por: Aran, Andrea, et al.
Publicado: (2022)

Defining the clonality of peripheral T cell lymphomas using RNA-seq
por: Brown, Scott D, et al.
Publicado: (2017)

PB2090: SYSTEMATIC LITERATURE REVIEW OF PROGNOSTIC FACTORS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Kumar, Shaji, et al.
Publicado: (2023)

Sampling strategies for sugarcane using either clonal replicates or diverse genotypes can bias the conclusions of RNA-Seq studies
por: Mello, Victor Hugo, et al.
Publicado: (2023)

Clonal dynamics and Stereo-seq resolve origin and phenotypic plasticity of adenosquamous carcinoma
por: Zhao, Ruiying, et al.
Publicado: (2023)

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
por: Bhatt, Parva, et al.
Publicado: (2023)

Endothelial progenitor cells display clonal restriction in multiple myeloma
por: Braunstein, Marc, et al.
Publicado: (2006)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Treatment of relapsed and refractory multiple myeloma
por: Lee, Ji Hyun, et al.
Publicado: (2020)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Cutaneous involvement in relapsed multiple myeloma
por: Salle, Valéry, et al.
Publicado: (2022)

A Focus on Relapsed Multiple Myeloma
por: Noonan, Kimberly, et al.
Publicado: (2022)

Prognostic significance of FSCN family in multiple myeloma
por: Deng, Cong, et al.
Publicado: (2021)

Clonal evolution of acute myeloid leukemia from diagnosis to relapse
por: Vosberg, Sebastian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4i5k0voo4c16fos2g7hkf70eld